Dr Hugo L Gallardo-Blanco, PhD - Hospital Universitario, Facultad de Medicina, UANL - Researcher

Dr Hugo L Gallardo-Blanco

PhD

Hospital Universitario, Facultad de Medicina, UANL

Researcher

Monterrey, NL | Mexico

Additional Specialties: Molecular biology, genetics, genomics

Dr Hugo L Gallardo-Blanco, PhD - Hospital Universitario, Facultad de Medicina, UANL - Researcher

Dr Hugo L Gallardo-Blanco

PhD

Introduction

Primary Affiliation: Hospital Universitario, Facultad de Medicina, UANL - Monterrey, NL , Mexico

Additional Specialties:

Research Interests:

Publications

14Publications

547Reads

3442Profile Views

24PubMed Central Citations

A clinical-pathogenetic approach on associated anomalies and chromosomal defects supports novel candidate critical regions and genes for gastroschisis.

Pediatr Surg Int 2018 Sep 9;34(9):931-943. Epub 2018 Aug 9.

Departamento de Genética, Facultad de Medicina y Hospital Universitario José Eleuterio González, Universidad Autónoma de Nuevo León, Ave. Madero y Gonzalitos S/N Col. Mitras Centro, CP 64460, Monterrey, Nuevo León, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00383-018-4331-4DOI Listing
September 2018
77 Reads
1.061 Impact Factor

Uridine 5'-diphospho-glucronosyltrasferase: Its role in pharmacogenomics and human disease.

Exp Ther Med 2018 Jul 18;16(1):3-11. Epub 2018 May 18.

Tecnologico de Monterrey, Medical School and Health Sciences, Monterrey, Nuevo Leon 64710, Mexico.

Biotransformation is an enzyme-catalyzed process in which the body converts endogenous compounds, xenobiotics and toxic substances into harmless or easily excreted metabolites. The biotransformation reactions are classified as phase I and II reactions. Uridine 5'-diphospho (UDP)-glucuronosyltransferases (UGTs) are a superfamily of phase II enzymes which have roles in the conjugation of xenobiotics or endogenous compounds, including drugs and bilirubin, with glucuronic acid to make them easier to excrete. The method the human body uses to achieve glucuronidation may be affected by a large interindividual variation due to changes in the sequences of the genes encoding these enzymes. In the last five years, the study of the genetic variants of the UGTs at a molecular level has become important due to its association with several diseases and the ability to predict adverse events due to drug metabolism. In the present review, the structure and the prominent genetic variants of the UGT1A subfamily and their metabolic and clinical implications are described.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.6184DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5995049PMC
July 2018
12 Reads
1 Citation
1.410 Impact Factor

Nanoparticles for death‑induced gene therapy in cancer (Review).

Mol Med Rep 2018 Jan 15;17(1):1413-1420. Epub 2017 Nov 15.

Department of Biochemistry and Molecular Medicine, Faculty of Medicine, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon 64460, Mexico.

Due to the high toxicity and side effects of the use of traditional chemotherapy in cancer, scientists are working on the development of alternative therapeutic technologies. An example of this is the use of death?induced gene therapy. This therapy consists of the killing of tumor cells via transfection with plasmid DNA (pDNA) that contains a gene which produces a protein that results in the apoptosis of cancerous cells. The cell death is caused by the direct activation of apoptosis (apoptosis?induced gene therapy) or by the protein toxic effects (toxin?induced gene therapy). The introduction of pDNA into the tumor cells has been a challenge for the development of this therapy. The most recent implementation of gene vectors is the use of polymeric or inorganic nanoparticles, which have biological and physicochemical properties (shape, size, surface charge, water interaction and biodegradation rate) that allow them to carry the pDNA into the tumor cell. Furthermore, nanoparticles may be functionalized with specific molecules for the recognition of molecular markers on the surface of tumor cells. The binding between the nanoparticle and the tumor cell induces specific endocytosis, avoiding toxicity in healthy cells. Currently, there are no clinical protocols approved for the use of nanoparticles in death?induced gene therapy. There are still various challenges in the design of the perfect transfection vector, however nanoparticles have been demonstrated to be a suitable candidate. This review describes the role of nanoparticles used for pDNA transfection and key aspects for their use in death?induced gene therapy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/mmr.2017.8091DOI Listing
January 2018
8 Reads
1 Citation
1.484 Impact Factor

Genetic variants in , and are associated with type 2 diabetes, BMI and dyslipidemia in families of Northeastern Mexico: A pilot study.

Exp Ther Med 2017 Feb 22;13(2):523-529. Epub 2016 Dec 22.

Department of Genetics, School of Medicine, Autonomous University of Nuevo León, Monterrey, Nuevo León, CP 64460, Mexico.

The aim of the present study was to investigate whether genetic markers considered risk factors for metabolic syndromes, including dyslipidemia, obesity and type 2 diabetes mellitus (T2DM), can be applied to a Northeastern Mexican population. A total of 37 families were analyzed for 63 single nucleotide polymorphisms (SNPs), and the age, body mass index (BMI), glucose tolerance values and blood lipid levels, including those of cholesterol, low-density lipoprotein (LDL), very LDL (VLDL), high-density lipoprotein (HDL) and triglycerides were evaluated. Three genetic markers previously associated with metabolic syndromes were identified in the sample population, including and . The SNP rs5210 was associated with T2DM, the SNP rs11196175 was associated with BMI and cholesterol and LDL levels, the SNP rs12255372 was associated with BMI and HDL, VLDL and triglyceride levels, and the SNP rs1885088 was associated with LDL levels (P<0.05).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2016.3990DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348709PMC
February 2017
223 Reads
2 Citations
1.410 Impact Factor

Candidate gene polymorphisms and risk of psoriasis: A pilot study.

Exp Ther Med 2016 Apr 9;11(4):1217-1222. Epub 2016 Feb 9.

Department of Genetics, University Hospital 'Dr. José Eleuterio González', Monterrey, Nuevo León 64460, México.

Psoriasis is a complex genetic disease, which has previously been associated with numerous single nucleotide polymorphisms (SNPs) that are implicated in various processes, including skin barrier functions and in the regulation of inflammatory and immune responses. The present study aimed to investigate the genotypic and allelic frequencies of 32 SNPs at 24 genetic loci, and their association with psoriasis in a Mexican population. These SNPs, which were associated with psoriasis in previous studies, included the following genes: Major histocompatibility complex class I-C (), interleukin ()-, , , , tumor necrosis factor ()-?, ring finger protein-114 (), cyclin-dependent kinase 5 regulatory subunit-associated protein 1-like 1, late cornified envelope 3B/3C, signal transducer and activator of transcription 4, , interferon induced with helicase C domain 1, , TNF-?-induced protein 3 (), interacting protein 1, endoplasmic reticulum aminopeptidase 1, TNF receptor-associated factor interacting protein 2, , nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor-alpha, F-box and leucine-rich repeat protein 19, nitric oxide synthase 2, cluster of differentiation 40, nuclear receptor coactivator 5, and metallopeptidase domain 33. A total of 32 male and 14 female subjects with a clinical diagnosis of chronic plaque psoriasis, as well as 103 control subjects, were analyzed. Molecular analyses were performed using TaqMan® assays in a TaqMan® OpenArray® Genotyping system. Results were analyzed using the Golden Helix SNP and Variation Suite 7 program. Of the 32 SNPs, six were associated with an increased risk of developing psoriasis, including: rs10484554 [allele T: odds ratio (OR) 3.51], rs3212227 (allele T: OR 1.88), IL-12B rs3213094 (allele C: OR 1.94), HLA complex group 27 rs1265181 (allele C: OR 2.83), annexin A6 rs17728338 (allele A: OR 2.41), and rs6125829 (allele G: OR 1.98). Fisher's exact test detected statistical significance; however, following false discovery rate and Bonferroni correction, this association was no longer significant (threshold for genome-wide significance, P<1.56×10). SNPs that were associated with an increased risk of psoriasis in the present study have previously been associated with psoriasis in European, American, and Asian populations. In order to establish genome-wide significance, future studies must analyze a greater sample size. To the best of our knowledge, the present pilot study is the first to investigate the association between these 32 SNPs and psoriasis in a Mexican Mestizo population.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2016.3066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4812537PMC
April 2016
20 Reads
8 Citations
1.410 Impact Factor

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers.

BMC Cancer 2016 Feb 8;16:74. Epub 2016 Feb 8.

Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León, Monterrey, NL, México.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-016-2062-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746878PMC
February 2016
30 Reads
4 Citations
3.362 Impact Factor

The tumor necrosis factor α (-308 A/G) polymorphism is associated with cystic fibrosis in Mexican patients.

PLoS One 2014 6;9(3):e90945. Epub 2014 Mar 6.

Departamento de Bioquimica y Medicina Molecular, Facultad de Medicina, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico; Centro de Investigacion y Desarrollo en Ciencias de la Salud, Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0090945PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3946307PMC
February 2015
27 Reads
3.234 Impact Factor

Detection of Turner Syndrome by quantitative PCR of SHOX and VAMP7 genes.

Genet Test Mol Biomarkers 2015 Feb 23;19(2):88-92. Epub 2014 Dec 23.

1 Departamento de Genética, Hospital Universitario "Dr. José Eleuterio González," Universidad Autónoma de Nuevo León, Monterrey , Nuevo León, México .

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/gtmb.2014.0236DOI Listing
February 2015
13 Reads

An investigation into the MMP1 gene promoter region polymorphism--1607 2G with recessive dystrophic epidermolysis bullosa disease severity in northeastern Mexican patients.

Int J Dermatol 2014 Aug 5;53(8):985-90. Epub 2014 Jun 5.

Department of Dermatology, Universidad Autónoma de Nuevo León, Hospital Universitario "Jose E. González", Monterrey, Mexico.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.12499DOI Listing
August 2014
30 Reads
1 Citation
1.230 Impact Factor

Nanoparticles vs cancer: a multifuncional tool.

Curr Top Med Chem 2014 Mar;14(5):664-75

Centro de investigacion en Materiales Avanzados, S. C. (CIMAV), Unidad Monterrey, Mexico.

View Article

Download full-text PDF

Source
March 2014
10 Reads
3 Citations
3.402 Impact Factor